This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Ronald Prussick, MD; Mahmoud A. M. Ali, MD, PhD; Donald Rosenthal, MD; Gordon Guyatt, MD

Arch Dermatol. 1992;128(2):210-213.

Abstract
• Objective.—
This study looked at whether oral vitamin C and vitamin E would protect the erythrocyte from oxidant damage caused by dapsone in patients with dermatitis herpetiformis.

Design.—
Fifteen consecutive patients with dermatitis herpetiformis taking dapsone therapy received, in addition, 800 U/d of vitamin E for 4 weeks; then 1000 mg of vitamin C per day for 4 weeks, and, finally, combined vitamin E and vitamin C therapy for 4 weeks. Hemolysis indexes were assessed at baseline and after each 4-week period.

Results.—
Statistical analysis of the results suggests that oral administration of 800 units of vitamin E daily for 4 weeks confers partial protective effect against dapsone-induced hemolysis in patients with dermatitis herpetiformis.

Conclusion.—
Partial protection against dapsone-induced hemolysis by orally administered vitamin E, if confirmed as being clinically relevant by further trials, may allow clinicians to continue dapsone therapy orally in patients who develop significant hemolysis. Prophylactic vitamin E to minimize potential hemolysis at the initiation of dapsone therapy may also be appropriate.

(Arch Dermatol. 1992;128:210-213)

Author Affiliations
From the Department of Medicine, Division of Dermatology, University of Toronto, Ontario (Dr Prussick); Department of Pathology, St Joseph's Hospital, Hamilton, Ontario (Dr Ali); and Departments of Pathology (Dr Ali), Medicine, Division of Dermatology, Faculty of Health Sciences (Dr Rosenthal), and Medicine and Clinical Epidemiology and Biostatistics (Dr Guyatt), McMaster University, Hamilton, Ontario.

Footnotes
Accepted for publication September 25, 1991.

Reprints not available.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Pharmacokinetic Profiles in Rats After Intravenous, Oral, or Dermal Administration of Dapsone
Helton et al.
Drug Metab. Dispos. 2000;28:925-929.
ABSTRACT | FULL TEXT  

Comparison of the Metabolism and Toxicity of Dapsone in Rat, Mouse and Man
Tingle et al.
J. Pharmacol. Exp. Ther. 1997;283:817-823.
ABSTRACT | FULL TEXT  

Management of Acquired Bullous Skin Diseases
Fine
NEJM 1995;333:1475-1484.
FULL TEXT